Has Andrew Ng, MD received payments from drug or device companies?

Yes. Drug and device makers reported $73 in general payments to Andrew Ng, MD across 5 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Andrew Ng, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Andrew Ng, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Andrew Ng, MD

Internal Medicine · Millbrae, CANPI 1871716910

Payments from drug & device makers

$73in general payments, 2019–2025

Across 5 payments — averaging $14.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sunovion Pharmaceuticals Inc.$73

What the payments were for

Food & beverage$73100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sunovion Pharmaceuticals Inc.	5	$73

How this compares

$73 in reported general payments places this provider in the 35th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California →

Medicare billing

Part B allowed, 2024

$633,466

Medicare patients

601

Services billed

6,056

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	593	$174,822
RebifInterferon Beta-1a/Albumin	27	$151,305
BiktarvyBictegrav/Emtricit/Tenofov Ala	14	$59,218
VelphoroSucroferric Oxyhydroxide	28	$32,957
JanuviaSitagliptin Phosphate	99	$28,100
NuedextaDextromethorphan Hbr/Quinidine	26	$19,771
XareltoRivaroxaban	62	$17,904
Sucralfate	99	$17,642
Pantoprazole Sodium	425	$17,333
FycompaPerampanel	25	$16,053
Spiriva HandihalerTiotropium Bromide	65	$15,690
LokelmaSodium Zirconium Cyclosilicate	33	$15,504
Sevelamer Carbonate	67	$15,298
Incruse ElliptaUmeclidinium Bromide	48	$13,840
Atorvastatin Calcium	1,249	$13,557

Paid to pharmacies, not to this prescriber.

Other internal medicine in Millbrae

Andrew ChengSouth San Francisco$55.1M
Joel NeutelTustin$34.9M
Donald BrandonSan Diego$34M
William TownerLos Angeles$27.4M
Rahul AggarwalSan Francisco$24M
Masoud AzizadNorthridge$21.1M
Helen StaceyWalnut Creek$20.4M
Rohit Loombala Jolla$15.1M
Zeid KayaliColton$14.2M
Alexandra DrakakiSanta Monica$14.2M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →